Evidence map›Paper›PMID 28599791›Full record

ArticleVaccine2017

Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.

Ying Ma, Andrew Yang, Shiwen Peng, Jin Qiu, Emily Farmer, Chien-Fu Hung, T-C Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Oncoimmunology · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ying MaDepartment of Gynecology and Obstetrics, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: mayingwuzhuoyi@126.com.
Andrew YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: ayang35@jhmi.edu.
Shiwen PengDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: speng@jhmi.edu.
Jin QiuDepartment of Obstetrics and Gynecology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: jeanqiuqiu@hotmail.com.
Emily FarmerDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: femily1@jhmi.edu.
Chien-Fu HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: chung2@jhmi.edu.
T-C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: wutc@jhmi.edu.
Johns Hopkins University · USShanghai Tenth People's Hospital · CNSouthern Medical University · CN

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259
6 · The paper itself

Abstract

Human papillomavirus (HPV) has been identified as the primary etiologic factor of cervical cancer, and subsets of anogenital and oropharyngeal cancers. HPV18 is the second most prevalent high-risk HPV type after HPV16. Furthermore, HPV18 is responsible for approximately 12% of cervical squamous cell carcinoma and 37% of cervical adenocarcinoma cases worldwide. In this study, we aimed to characterize the HPV18-E6-specific epitope and establish an HPV18 animal tumor model to evaluate the E6-specific immune response induced by our DNA vaccine. We vaccinated naïve C57BL/6 mice with a prototype DNA vaccine, pcDNA3-HPV18-E6, via intramuscular injection followed by electroporation, and analyzed the E6-specific CD8+ T cell responses by flow cytometry using a reported T cell epitope. We then characterized the MHC restriction element for the characterized HPV18-E6 epitope. Additionally, we generated an HPV18-E6-expressing tumor cell line to study the antitumor effect mediated by E6-specific immunity. We observed a robust HPV18-E6aa67-75 peptide-specific CD8+ T cell response after vaccination with pcDNA3-HPV18-E6. Further characterization demonstrated that this epitope was mainly restricted by H-2K

Indexed as

AdenocarcinomaAnimalsCarcinoma, Squamous CellCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationDisease Models, AnimalDNA-Binding ProteinsFemaleHuman papillomavirus 18Injections, IntramuscularMice, Inbred C57BLOncogene Proteins, ViralPapillomavirus InfectionsPapillomavirus VaccinesVaccines, DNADNA-Binding ProteinsE6 protein, Human papillomavirus type 18Oncogene Proteins, ViralPapillomavirus VaccinesVaccines, DNADNA vaccineE6 oncoproteinHPV18-E6 tumor modelHuman papillomavirus 18Immunotherapy

Identifiers

PMID28599791
PMCPMC5524135
OpenAlexW2623186824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.